The current monkeypox Jynneos vaccine supply has been reportedly uneven helping to meet demand for some some where as still a hurdle to get vaccine for others, CNN writes.

Claire Hannan, executive director of the Association of Immunization Managers, told CNN “The situation does vary geographically.” The US Department of Health and Human Services (DHHS) has reportedly distributed almost 1.1 million vials of ‘Bavarian Nordic’s Jynneos monkeypox vaccine’ to various various monkeypox hot spots in the country.

The US Centers for Disease Control and Prevention (CDC) and the California Department of Health have reportedly have provided guidance on how to switch to the intradermal technique “as a safe and effective way to vaccinate more people, as well as a requirement to receive additional vaccine allotments”, the San Francisco Department of Public Health told CNN.

Lucy Caldwell, a spokesperson for the Fairfax County Health Department, told CNN “the intradermal or ID method of administering vaccine is expected to help provide monkeypox vaccinations to this broader group of eligible people”.

Dr. Emily Volk, president of the College of American Pathologists, told CNN “It’s a little too early to tell how it’s going to help with the supply meeting demand, but I think logically, you use less vaccine for one person. This is a dose-sparing approach, so it’s going to allow for the doses that we do have to be usable for many more people. So, to me that is very positive and I am actually heartened that the public health community is thinking outside the box. It also buys time to make more vaccine.”

Dr. Philip Huang, director of the Dallas County Health and Human Services Department, told CNN “We have more vaccine available now. We expanded the criteria, and the calls are slowing down a little bit. So, we have more appointments available now. They’re not all getting filled in, about the vaccination appointments. We’re having more no-shows.”